<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2023-3-76-81</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group></article-categories><title-group><article-title>Применение анакинры у пациентки с подагрой, длительно наблюдавшейся с диагнозом ревматоидного артрита</article-title><trans-title-group xml:lang="en"><trans-title>The use of anakinra in a patient with gout and long-term follow-up of rheumatoid arthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4383-9872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черёмушкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cheremushkina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черёмушкина Елена Владимировна,</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Cheryomushkina Elena Vladimirovna,</p><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">buipvybho@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6862-2645</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семашко</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Semashko</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9292-6649</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А;</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522;2/1, Barrikadnaya Street, Build. 1, Moscow 125993</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology;&#13;
Russian Medical Academy of Continuing Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>07</month><year>2023</year></pub-date><volume>17</volume><issue>3</issue><fpage>76</fpage><lpage>81</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Черёмушкина Е.В., Елисеев М.С., Семашко А.С., Алексеева А.В., Лила А.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Черёмушкина Е.В., Елисеев М.С., Семашко А.С., Алексеева А.В., Лила А.М.</copyright-holder><copyright-holder xml:lang="en">Cheremushkina E.V., Eliseev M.S., Semashko A.S., Alekseeva A.V., Lila A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1435">https://mrj.ima-press.net/mrj/article/view/1435</self-uri><abstract><p>Подагра является хронической воспалительной артропатией, которая вызвана отложением суставных и периартикулярных кристаллов моноурата натрия (МУН) в условиях хронической гиперурикемии и относится к группе аутовоспалительных заболеваний, характеризующихся активацией врожденного звена иммунитета. В ряде случаев, особенно у женщин, при длительном течении заболевания и отсутствии адекватной терапии выявляется хронический артрит, мало отличимый от такового при ревматоидном артрите (РА). При этом до недавнего времени сочетание РА и подагры считалось казуистикой ввиду ингибирования кристаллообразования специфическими факторами, ассоциированными с РА, а механизмы развития воспаления, свойственные этим заболеваниям, – абсолютно различными. Однако, по последним данным, возможно сосуществования этих двух заболеваний у одного пациента, а терапия как подагры, так и РА (у части пациентов) может быть успешной при назначении генно-инженерных биологических препаратов, в частности ингибиторов рецептора интерлейкина 1 (ИЛ1р).</p><p>В статье представлен редкий клинический случай хронической тофусной подагры у пожилой пациентки, длительно наблюдавшейся с диагнозом РА, у которой достигнуто значимое улучшение при терапии антагонистом ИЛ1р анакинрой.</p></abstract><trans-abstract xml:lang="en"><p>Gout is a chronic inflammatory arthropathy, caused by articular and periarticular sodium monourate (MUN) crystals deposition on the background of chronic hyperuricemia. Gout belongs to the group of autoinflammatory diseases characterized by activation of the innate immune system. In some cases, especially in women, with a long course of the disease and absence of adequate therapy, chronic arthritis is detected, which has little difference from that in rheumatoid arthritis (RA). At the same time, until recently, the combination of RA and gout was considered casuistry due to the inhibition of crystal formation by specific factors associated with RA, what is more mechanisms of inflammation development characteristic of these diseases are completely different. However, according to the latest data, the coexistence of these two diseases in one patient is possible, and the therapy of both, gout and RA (in some patients) can be successful when prescribing biological disease modifying antirheumatic drugs, in particular inhibitors of the interleukin 1 receptor (IL1r).</p><p>The article presents a rare clinical case of chronic tophi gout in an elderly patient who was followed up for a long time with a diagnosis of RA, a significant improvement was achieved on therapy with the IL1r antagonist anakinra.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>подагра</kwd><kwd>ревматоидный артрит</kwd><kwd>дифференциальная диагностика</kwd><kwd>анакинра</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gout</kwd><kwd>rheumatoid arthritis</kwd><kwd>differential diagnosis</kwd><kwd>anakinra</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Komatsu N, Takayanagi H. Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol. 2012 Apr 13;3:77. doi: 10.3389/fimmu.2012.00077.</mixed-citation><mixed-citation xml:lang="en">Komatsu N, Takayanagi H. Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol. 2012 Apr 13;3:77. doi: 10.3389/fimmu.2012.00077.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Баймухамедов Ч. Ревматоидный артрит у пожилых: взгляд практического ревматолога. Научно-практическая ревматология. 2020;58(4):447-50.</mixed-citation><mixed-citation xml:lang="en">Baimukhamedov Ch. Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist. Nauchno-prakticheskaya revmatologiya. 2020;58(4):447-50. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Villa-Blanco JI, Calvo-Alen J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging. 2009;26(9):739-50. doi: 10.2165/11316740-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Villa-Blanco JI, Calvo-Alen J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging. 2009;26(9):739-50. doi: 10.2165/11316740-000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020 Jul;16(7):380-90. doi: 10.1038/s41584-020-0441-1.</mixed-citation><mixed-citation xml:lang="en">Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020 Jul;16(7):380-90. doi: 10.1038/s41584-020-0441-1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018 Jul;77(7):1048-52. doi: 10.1136/annrheumdis-2017-212288.</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018 Jul;77(7):1048-52. doi: 10.1136/annrheumdis-2017-212288.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Черёмушкина ЕВ, Елисеев МС. Гиперурикемия и подагра: влияние на костный метаболизм и суставной хрящ (обзор литературы). Ожирение и метаболизм. 2022; 19(3):348-57.</mixed-citation><mixed-citation xml:lang="en">Cheremushkina EV, Eliseev MS. Hyperuricemia and gout: effects on bone and articular cartilage (literature review). Ozhirenie i metabolizm. 2022;19(3):348-57. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Khosla P, Gogia A, Agarwal PK, et al. Concomitant gout and rheumatoid arthritis – a case report. Indian J Med Sci. 2004 Aug;58(8):349-52.</mixed-citation><mixed-citation xml:lang="en">Khosla P, Gogia A, Agarwal PK, et al. Concomitant gout and rheumatoid arthritis – a case report. Indian J Med Sci. 2004 Aug;58(8):349-52.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo CF, Tsai WP, Liou LB. Rare copresent rheumatoid arthritis and gout: comparison with pure rheumatoid arthritis and a literature review. Clin Rheumatol. 2008 Feb;27(2):231-5. doi: 10.1007/s10067-007-0771-2.</mixed-citation><mixed-citation xml:lang="en">Kuo CF, Tsai WP, Liou LB. Rare copresent rheumatoid arthritis and gout: comparison with pure rheumatoid arthritis and a literature review. Clin Rheumatol. 2008 Feb;27(2):231-5. doi: 10.1007/s10067-007-0771-2.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Чикаленкова НА, Барскова ВГ. Клинические особенности подагры у женщин: результаты сравнительного исследования. Научно-практическая ревматология. 2014;52(2):178-82.</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Chikalenkova NA, Barskova VG. Clinical features of gout in women: the results of a comparative study. Nauchno-prakticheskaya revmatologiya. 2014;52(2):178-82. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Самсонов МЮ. Роль интерлейкина 1 в развитии заболеваний человека: фокус на анакинре (рецепторном антагонисте ИЛ-1). Научно-практическая ревматология. 2022;60(3):280-98.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Samsonov MYu. The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist). Nauchno-prakticheskaya revmatologiya. 2022;60(3):280-98. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Елисеев МС. Резолюция Совета экспертов (16 июня 2022 г.): Терапия подагрического артрита ингибитором ИЛ-1 (анакинра). Научно-практическая ревматология. 2022;60(6):638-41.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Eliseev MS. Resolution of the Council of Excperts (16th June, 2022): Therapy of gouty arthritis with an IL-1 inhibitor (anakinra). Nauchno-prakticheskaya revmatologiya. 2022;60(6):638-41. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Сукмарова ЗН, Попкова ТВ и др. Проблемы иммунопатологии и перспективы фармакотерапии идиопатического рецидивирующего перикардита: применение ингибитора интерлейкина 1 (Анакинра). Научно-практическая ревматология. 2023;61(1):47-61.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Sukmarova ZN, Popkova TV, et al. Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra). Nauchno-prakticheskaya revmatologiya. 2023;61(1):47-61. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388 (10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3.</mixed-citation><mixed-citation xml:lang="en">Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388 (10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Dai C, Wang C, Xia F, et al. Age and Gender-Specific Reference Intervals for Uric Acid Level in Children Aged 5-14 Years in Southeast Zhejiang Province of China: Hyperuricemia in Children May Need Redefinition. Front Pediatr. 2021 Nov 10;9:560720. doi: 10.3389/fped.2021.560720.</mixed-citation><mixed-citation xml:lang="en">Dai C, Wang C, Xia F, et al. Age and Gender-Specific Reference Intervals for Uric Acid Level in Children Aged 5-14 Years in Southeast Zhejiang Province of China: Hyperuricemia in Children May Need Redefinition. Front Pediatr. 2021 Nov 10;9:560720. doi: 10.3389/fped.2021.560720.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Harlow SD, Gass M, Hall JE, et al; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril. 2012 Apr;97(4):843-51. doi: 10.1016/j.fertnstert.2012.01.128.</mixed-citation><mixed-citation xml:lang="en">Harlow SD, Gass M, Hall JE, et al; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril. 2012 Apr;97(4):843-51. doi: 10.1016/j.fertnstert.2012.01.128.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol. 2009 Jun 1;169(11):1352-61. doi: 10.1093/aje/kwp043.</mixed-citation><mixed-citation xml:lang="en">Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol. 2009 Jun 1;169(11):1352-61. doi: 10.1093/aje/kwp043.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women – the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10(5):R116. doi: 10.1186/ar2519. Epub 2008 Sep 26.</mixed-citation><mixed-citation xml:lang="en">Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women – the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10(5):R116. doi: 10.1186/ar2519. Epub 2008 Sep 26.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010 Jul;69(7):1305-9. doi: 10.1136/ard.2009.109884.</mixed-citation><mixed-citation xml:lang="en">Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010 Jul;69(7):1305-9. doi: 10.1136/ard.2009.109884.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nada D, Gaber R, Mahmoud AS, et al. Hyperuricemia Among Egyptian Rheumatoid Arthritis Patients. Is It an Association or an Inflammatory Marker? A Cross-Sectional Observational Study. Open Access Rheumatol. 2021 Oct 5;13:305-14. doi: 10.2147/OARRR. S331488.</mixed-citation><mixed-citation xml:lang="en">Nada D, Gaber R, Mahmoud AS, et al. Hyperuricemia Among Egyptian Rheumatoid Arthritis Patients. Is It an Association or an Inflammatory Marker? A Cross-Sectional Observational Study. Open Access Rheumatol. 2021 Oct 5;13:305-14. doi: 10.2147/OARRR. S331488.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41. doi: 10.1002/art.30520.</mixed-citation><mixed-citation xml:lang="en">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41. doi: 10.1002/art.30520.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ljubojevic M, Herak-Kramberger CM, Hagos Y, et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am J Physiol Renal Physiol. 2004 Jul;287(1):F124-38. doi: 10.1152/ajprenal.00029.2004.</mixed-citation><mixed-citation xml:lang="en">Ljubojevic M, Herak-Kramberger CM, Hagos Y, et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am J Physiol Renal Physiol. 2004 Jul;287(1):F124-38. doi: 10.1152/ajprenal.00029.2004.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973 Feb 24;1(5851): 449-51. doi: 10.1136/bmj.1.5851.449.</mixed-citation><mixed-citation xml:lang="en">Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973 Feb 24;1(5851): 449-51. doi: 10.1136/bmj.1.5851.449.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gordon TP, Ahern MJ, Reid C, et al. Studies on the interaction of rheumatoid factor with monosodium urate crystals and case report of coexistent tophaceous gout and rheumatoid arthritis. Ann Rheum Dis. 1985 Jun; 44(6):384-9. doi: 10.1136/ard.44.6.384.</mixed-citation><mixed-citation xml:lang="en">Gordon TP, Ahern MJ, Reid C, et al. Studies on the interaction of rheumatoid factor with monosodium urate crystals and case report of coexistent tophaceous gout and rheumatoid arthritis. Ann Rheum Dis. 1985 Jun; 44(6):384-9. doi: 10.1136/ard.44.6.384.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Scott JT. Gout. Ann Rheum Dis. 1983 Aug;42 Suppl 1(Suppl 1):16-8. doi: 10.1136/ard.42.suppl_1.16.</mixed-citation><mixed-citation xml:lang="en">Scott JT. Gout. Ann Rheum Dis. 1983 Aug;42 Suppl 1(Suppl 1):16-8. doi: 10.1136/ard.42.suppl_1.16.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Turner RA, Counts GB, Treadway WJ, et al. Rheumatoid factor and monosodium urate crystalneutrophil interactions in gouty inflammation. Inflammation. 1981 Dec;5(4):353-61. doi: 10.1007/BF00911099.</mixed-citation><mixed-citation xml:lang="en">Turner RA, Counts GB, Treadway WJ, et al. Rheumatoid factor and monosodium urate crystalneutrophil interactions in gouty inflammation. Inflammation. 1981 Dec;5(4):353-61. doi: 10.1007/BF00911099.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kozin F, McCarty DJ. Rheumatoid factors in the serum of gouty patients. Arthritis Rheum. 1977 Nov-Dec;20(8):1559-60. doi: 10.1002/art.1780200823.</mixed-citation><mixed-citation xml:lang="en">Kozin F, McCarty DJ. Rheumatoid factors in the serum of gouty patients. Arthritis Rheum. 1977 Nov-Dec;20(8):1559-60. doi: 10.1002/art.1780200823.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Rizzoli AJ, Trujeque L, Bankhurst AD. The coexistence of gout and rheumatoid arthritis: case reports and a review of the literature. J Rheumatol. 1980 May-Jun;7(3):316-24.</mixed-citation><mixed-citation xml:lang="en">Rizzoli AJ, Trujeque L, Bankhurst AD. The coexistence of gout and rheumatoid arthritis: case reports and a review of the literature. J Rheumatol. 1980 May-Jun;7(3):316-24.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Jebakumar AJ, Udayakumar PD, Crowson CS, et al. Occurrence of gout in rheumatoid arthritis: it does happen! A populationbased study. Int J Clin Rheumtol. 2013 Aug;8(4):433-7. doi: 10.2217/ijr.13.45.</mixed-citation><mixed-citation xml:lang="en">Jebakumar AJ, Udayakumar PD, Crowson CS, et al. Occurrence of gout in rheumatoid arthritis: it does happen! A populationbased study. Int J Clin Rheumtol. 2013 Aug;8(4):433-7. doi: 10.2217/ijr.13.45.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 2002 Jul;9(3):161-75. doi: 10.1038/sj.mn.7800136.</mixed-citation><mixed-citation xml:lang="en">Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 2002 Jul;9(3):161-75. doi: 10.1038/sj.mn.7800136.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Vorbach C, Harrison R, Capecchi MR. Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol. 2003 Sep;24(9):512-7. doi: 10.1016/s1471-4906(03)00237-0.</mixed-citation><mixed-citation xml:lang="en">Vorbach C, Harrison R, Capecchi MR. Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol. 2003 Sep;24(9):512-7. doi: 10.1016/s1471-4906(03)00237-0.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008 Aug;27(8): 967-78. doi: 10.1080/15257770802257952.</mixed-citation><mixed-citation xml:lang="en">Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008 Aug;27(8): 967-78. doi: 10.1080/15257770802257952.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ramirez J, Caсete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018 Jul; 17(7):727-32. doi: 10.1080/14740338.2018.1486819. Epub 2018 Jun 14.</mixed-citation><mixed-citation xml:lang="en">Ramirez J, Caсete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018 Jul; 17(7):727-32. doi: 10.1080/14740338.2018.1486819. Epub 2018 Jun 14.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004 Jun;43 Suppl 3:iii2-iii9. doi: 10.1093/rheumatology/keh201.</mixed-citation><mixed-citation xml:lang="en">Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004 Jun;43 Suppl 3:iii2-iii9. doi: 10.1093/rheumatology/keh201.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kondo Y, Suzuki K, Inoue Y, et al. Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis. Arthritis Res Ther. 2019 Jan 10;21(1):14. doi: 10.1186/s13075-018-1802-x.</mixed-citation><mixed-citation xml:lang="en">Kondo Y, Suzuki K, Inoue Y, et al. Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis. Arthritis Res Ther. 2019 Jan 10;21(1):14. doi: 10.1186/s13075-018-1802-x.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Labrousse M, Kevorkian-Verguet C, Boursier G, et al. Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review. Crit Rev Clin Lab Sci. 2018 Sep;55(6): 432-42. doi: 10.1080/10408363.2018.1488805.</mixed-citation><mixed-citation xml:lang="en">Labrousse M, Kevorkian-Verguet C, Boursier G, et al. Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review. Crit Rev Clin Lab Sci. 2018 Sep;55(6): 432-42. doi: 10.1080/10408363.2018.1488805.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-prakticheskaya revmatologiya. 2016; 54(1):60-77. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Nikfar S, Saiyarsarai P, Tigabu BM, et al. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2018 Aug; 38(8):1363-83. doi: 10.1007/s00296-018-4041-1.</mixed-citation><mixed-citation xml:lang="en">Nikfar S, Saiyarsarai P, Tigabu BM, et al. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2018 Aug; 38(8):1363-83. doi: 10.1007/s00296-018-4041-1.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Saag KG, Khanna PP, Keenan RT, et al. A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis Rheumatol. 2021 Aug;73(8):1533-42. doi: 10.1002/art.41699.</mixed-citation><mixed-citation xml:lang="en">Saag KG, Khanna PP, Keenan RT, et al. A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis Rheumatol. 2021 Aug;73(8):1533-42. doi: 10.1002/art.41699.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Jeria-Navarro S, Gomez-Gomez A, Park HS, et al. Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature. Front Med (Lausanne). 2023 Jan 12;9:1089993. doi: 10.3389/fmed.2022.1089993.</mixed-citation><mixed-citation xml:lang="en">Jeria-Navarro S, Gomez-Gomez A, Park HS, et al. Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature. Front Med (Lausanne). 2023 Jan 12;9:1089993. doi: 10.3389/fmed.2022.1089993.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Herrero-Beites AM, Alonso-Ruiz A, et al. SAT0367 Low-Dose Anakinra is Effective for the Prophylaxis of Acute Episodes of Inflammation In Severe Tophaceous Gout. Ann Rheum Dis. 2013;72:A707-A708.</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Herrero-Beites AM, Alonso-Ruiz A, et al. SAT0367 Low-Dose Anakinra is Effective for the Prophylaxis of Acute Episodes of Inflammation In Severe Tophaceous Gout. Ann Rheum Dis. 2013;72:A707-A708.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
